Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tranexamic acid for reducing blood loss in pediatric hip osteotomies
NL-OMON51297Phase 4Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in hip dysplasia (DDH) and hip dislocation comparing Tranexamic acid with Placebo (2 arms). Primary endpoint: Estimated intraoperative blood loss. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
tranexamic acid
03
Conditions
hip dysplasia (DDH)hip dislocation
Beyond the preview
Go deeper on NL-OMON51297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51297.